Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CoLucid Pharmaceuticals, Inc.

http://colucid.com/

Latest From CoLucid Pharmaceuticals, Inc.

Finance Watch: $1.32bn In New Biopharma VC Financings As Year-End Approaches

Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.

Financing Innovation

Lilly Expands Migraine Franchise With Reyvow Approval

Reyvow gives Lilly a second MOA in migraine, following the anti-CGRP biologic Emgality, and adds an acute therapy to the preventive agent approved in 2018.

Approvals Business Strategies

Lilly's Lasmiditan NDA Review Could Hinge On US FDA's Migraine Guidance

Potential first-in-class on-demand oral migraine treatment would complement new prevention products from Lilly, Amgen and Teva. 

Neurology Drug Review

Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?

Galcanezumab was able to reduce episodic cluster headaches compared to placebo, but missed statistical significance for chronic cluster headaches. Amgen’s Aimovig still is first in line to reach the market in the anti-CGRP class.

Neurology Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register